TAKANOBU KAN

Last Updated :2025/06/09

Affiliations, Positions
Hiroshima University Hospital(Medical), Associate Professor or Lecturer
E-mail
tkanhiroshima-u.ac.jp

Basic Information

Major Professional Backgrounds

  • 2023/08/01, Hiroshima University, Hospital, Lecturer

Educational Backgrounds

  • Hiroshima University, Graduate School of Biomedical Sciences, Japan, 2011/04, 2015/05
  • Toyama Medical and Pharmaceutical University, Japan, 1998/04, 2004/03

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Dermatology
  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Dermatology

Research Keywords

  • malignant melanoma, squamous cell carcinoma, basal cell carcinoma, extramammary paget's disease, burn, wound healing, regenerative medicine

Affiliated Academic Societies

  • Japanese Dermatological Association, 2006
  • Japanese society of burn Injuries, 2009
  • Japanese Skin Cancer Society, 2009
  • Japan Society of Plastic and Reconstructive Surgery
  • The Japanese Association of Dermatologic Surgery, 2009
  • Japanese Organization of Clinical Dermatologists, 2006

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment II
  2. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2025, Undergraduate Education, Intensive, Practice of Medicine II
  4. 2025, Undergraduate Education, 2Term, Dermatology

Research Activities

Academic Papers

  1. A case of malignant melanoma in which adalimumab was effective for steroid-resistant uveitis caused by dabrafenib/trametinib combination therapy, J Dermatol, 52(5), 334-336, 202505
  2. Axillary web syndrome with vascular thrombosis and arterial intimal hyperplasia, JAAD Case Reports, 16(34), 32-35, 2023
  3. Uveitis associated with immune checkpoint inhibitors or BRAF/MEK inhibitors in patients with malignant melanoma, MELANOMA RESEARCH, 33(6), 539-546, 202312
    Link to Paper Search Results by DOI
  4. Immunological Changes of Basophil Hyperreactivity to Sweat in Patients With Well-Controlled Atopic Dermatitis, FRONTIERS IN IMMUNOLOGY, 13, 20220629
    Link to Paper Search Results by DOI
  5. Longitudinal prevalence of atopic dermatitis among freshmen at Hiroshima University between 2002 and 2019, JOURNAL OF DERMATOLOGY, 49(7), 724-728, 202207
    Link to Paper Search Results by DOI
  6. Clinical course of more than 10 years in a patient with extensive skin burns who received cultured epidermal autograft transplantation, REGENERATIVE THERAPY, 19, 154-157, 202203
    Link to Paper Search Results by DOI
  7. ★, Evaluation of recombinant MGL_1304 produced by Pichia pastoris for clinical application to sweat allergy, Allergology International, 64(3), 266-271, 2015
  8. Sweat allergy: Extrinsic or intrinsic?, JOURNAL OF DERMATOLOGICAL SCIENCE, 87(1), 3-9, 201707
    Link to Paper Search Results by DOI
  9. Disseminated Subcutaneous Phaeohyphomycosis caused by Exophiala ologosperma in a Patient with Wegeners Granulomatosis, Acta Dermato-venereologica, 93(3), 356-357, 2013
  10. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients, Journal of Allergy and Clinical Immunology, 132(3), 608-615, 2013
  11. A human monoclonal IgE antibody that binds to MGL_1304, a major allergen in human sweat, without activation of mast cells and basophils, Biochemical and Biophysical Research Communications, 488(42737), 99-104, 2015
  12. Case of cholinergic urticaria accompanied by anaphylaxis, JOURNAL OF DERMATOLOGY, 44(11), 1291-1294, 201711
    Link to Paper Search Results by DOI
  13. A unique clinical phenotype of a patient bearing a newly identified deletion mutation in the PSENEN gene along with the pathogenic serum desmoglein-1 antibody, Clinical and Experimental Dermatology, 43(3), 329-332, 201804
  14. Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis, Internal Medicine, 53(16), 1873-1875
  15. Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma, JOURNAL OF DERMATOLOGY, 47(8), 907-910, 202008
    Link to Paper Search Results by DOI
  16. Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin., European Journal of Hospital Pharmacy, 27(2), 128-128, 202003
  17. Calculation of practical skin donor area for meshed skin grafting in real-world surgery, DERMATOLOGIC THERAPY, 33(6), 202011
    Link to Paper Search Results by DOI
  18. The relationship between the development of erythroderma in patients with atopic dermatitis and the avoidance of anti-inflammatory topical drugs., Allergology International, 20, 202107
  19. Time course of disease severity from birth to 19 years old in patients with moderate to severe atopic dermatitis in adulthood., journal of Dermatology, 48, 205-206, 202105
  20. Malignant melanoma with in-transit metastases refractory to programmed cell death-1 inhibitor successfully treated with local interferon-beta injections: A case report, MOLECULAR AND CLINICAL ONCOLOGY, 15(4), 202110
    Link to Paper Search Results by DOI
  21. Comparison of the time course of atopic dermatitis from birth to 19 years old among generations of patients in Japan, JOURNAL OF DERMATOLOGY, 48(10), 1602-1606, 202110
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Investigation of efficient skin biopsy in Intravenous Large B-Cell Lymphoma, Hayato Mizuno, Takanobu Kan, Shunsuke Takahagi, Mikio Kawai, Michihiro Hide, Akio Tanaka, 25th World Congress of Dermatology, 2023/07, Without Invitation, English
  2. Clinical risk factors predicting full thickness defect of nasal ala in basal cell carcinoma, Takanobu Kan, Hayato Mizuno, Akio Tanaka, 25th World Congress of Dermatology, 2023/07, Without Invitation, English
  3. Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment : report of five cases., Daiki Matsubara, Takanobu Kan, Michihiro Hide, 10th World Congress of Melanoma, 2021/04/15, Without Invitation, English
  4. TLR2 activation enhances IL-4 receptor signaling and response in human Langerhans cells., Yi. Pan, Takanobu Kan, Thomas Bieber, 16th International Workshop on Langerhans Cells, 2019/10/03, Without Invitation, English, Mainz, Germany
  5. Eight cases of metastatic extramammary Paget's disease successfully treated with monthly docetaxel chemotherapy with or without TS-1., Takanobu Kan, Mikio Kawai, Risa Otsuka, Shunsuke Takahagi and Michihiro Hide, 2019/06/10, Without Invitation, English, Milan, Italy
  6. Toll-like receptor 1/2 ligand enhances IL-4 receptor signaling in human Langerhans cells., International Investigative Dermatology 2018, 2018/05, Without Invitation, English, Toll-like receptor 2 (TLR2) on human dendritic cells (DCs) recognizes bacterial components from Staphylococcus aureus which is present in over 80 % of atopic dermatitis (AD) skin lesion. DCs secrete cytokines and chemokines, and thus orchestrate T cell responses. In AD, it is considered that Th2 inflammatory response dominate the acute phase. IL-4 plays an important role in AD patients and treatment with Dupilumab, a monoclonal antibody against IL-4 receptor subunit alpha (IL-4R), shows significantly improvements for AD patients. TLR2 is expected to have an interaction with IL-4R. Thus, we investigated the functional relevance between TLR2 and IL-4R in human Langerhans cells (LCs). LCs (CD34LCs) were generated from CD34+ progenitor cells in vitro. CD34LCs were treated with IL-4 and/or TLR1/2 agonist Pam3Cys and IL-4R complexes were analyzed on mRNA and protein level by real-time PCR (RT-qPCR) and flow cytometry (FCM), respectively. The effects of Pam3Cys pretreatment on IL-4R signaling via signal transducer and activator of transcription 6 (STAT6) phosphorylation analysis and production of Th2 chemokines in CD34LCs were investigated by FCM, RT-qPCR and enzyme-linked immunosorbent assay. Although mRNA levels of all IL-4R subunits were increased with Pam3Cys stimulation, only IL-2 receptor subunit gamma (IL-2R) was upregulated on CD34LCs cell surface. STAT6 was activated by IL-4 and even stronger by pretreatment with Pam3Cys. Pam3Cys alone did not activate STAT6. CCL17 synergistically increased with combined stimulation, while CCL13 increased additively. Anti-IL-4R antibody inhibited the production of CCL17 and CCL13 by IL-4. These results show that Pam3Cys enhances IL-4R signaling by upregulating the expression of IL-2R Hence, the inflammatory response induced by IL-4 is more likely to be caused in patients with AD who are susceptible to S. aureus colonization.
  7. Two cases of malignant melanoma treated with BRAF/MEK inhibitors followed by premeditated switch to anti-Programmed Death-1 antibody., Asuka Amano, Satoshi Tsuboi, Takanobu Kan, Maiko Tanaka,Mikio Kawai, Michihiro Hide, The 5th Eastern Asia Dermatology Congress, 2018/06, Without Invitation, English

Awards

  1. 2019, Travel grant, 16th International Workshop on Langerhans Cells, TLR2 activation enhances IL-4 receptor signaling and response in ID 05 human Langerhans cells.

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Scientific Research (C)), 2023, 2025
  2. 2023, 2025
  3. 2022, 2022
  4. 2018/09/01, 2019/03/31
  5. 2018/09/01, 2020/03/31
  6. 2018/10, 2019/03
  7. 2018, 2018

Social Activities

History as Peer Reviews of Academic Papers

  1. 2025, J Dermatol, Others, 1
  2. 2021, journal of dermatology, 1
  3. 2020, The Journal of Dermatology, Others, 1